<html lang="en" class="pb-page js" data-request-id="94d6de2914b00120-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6de2914b00120-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/i64AwFbgC3RYJ-h_IVJKA2N4SrJfJXWvPrU-t6mV7qfLyFlYKkOdylLT-jMaKw8FeUIPZJhCkQcykHtf2oZ0DA=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6de2914b00120-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.6515802843557543"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Hematology/Oncology">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Breast Cancer|Treatments in Oncology"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2202809","title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","category":"Research","type":"Original Article","topics":"Breast Cancer|Treatments in Oncology","specialties":"Hematology/Oncology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2022-07-21T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Hematology/Oncology\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Breast Cancer|Treatments in Oncology\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2202809","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Research Summary","title":"Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer","doi":"10.1056/NEJMdo006592","issueDate":"2022-07-21T00:00Z","age":"6Months-1990","isFree":"n","topics":"Breast Cancer|Treatments in Oncology","viewType":"Full","specialties":"Hematology/Oncology"},{"type":"Quick Take","title":"Pembrolizumab and Overall Survival in Triple-Negative Breast Cancer","doi":"10.1056/NEJMdo006591","issueDate":"2022-07-21T00:00Z","age":"6Months-1990","isFree":"n","topics":"Breast Cancer|Treatments in Oncology","viewType":"Full","specialties":"Hematology/Oncology"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6de2914b00120-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer"><meta name="dc.Creator" content="Javier Cortes"><meta name="dc.Creator" content="Hope S. Rugo"><meta name="dc.Creator" content="David W. Cescon"><meta name="dc.Creator" content="Seock-Ah Im"><meta name="dc.Creator" content="Mastura M. Yusof"><meta name="dc.Creator" content="Carlos Gallardo"><meta name="dc.Creator" content="Oleg Lipatov"><meta name="dc.Creator" content="Carlos H. Barrios"><meta name="dc.Creator" content="Jose Perez-Garcia"><meta name="dc.Creator" content="Hiroji Iwata"><meta name="dc.Creator" content="Norikazu Masuda"><meta name="dc.Creator" content="Marco Torregroza Otero"><meta name="dc.Creator" content="Erhan Gokmen"><meta name="dc.Creator" content="Sherene Loi"><meta name="dc.Creator" content="Zifang Guo"><meta name="dc.Creator" content="Xuan Zhou"><meta name="dc.Creator" content="Vassiliki Karantza"><meta name="dc.Creator" content="Wilbur Pan"><meta name="dc.Creator" content="Peter Schmid"><meta name="dc.Description" content="In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-..."><meta name="Description" content="In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2022-07-21"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2202809"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202207213870307"><meta name="dc.Language" content="EN"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2022 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2202809">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2202809">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2202809">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer | NEJM">
        <meta property="og:title" content="Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2202809">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/f60485f3-d7d0-42d9-bcc1-03dd84ff0a69/nejmoa2202809_f0.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/f60485f3-d7d0-42d9-bcc1-03dd84ff0a69/nejmoa2202809_f0.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy
resulted in longer progression-free survival than chemotherapy alone among patients
with advanced triple-...">
        <meta name="twitter:description" content="In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy
resulted in longer progression-free survival than chemotherapy alone among patients
with advanced triple-...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3416">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2202809">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2202809">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:MMS NextGen Website Group;article:article:doi\:10.1056/NEJMoa2202809;issue:issue:doi\:10.1056/nejm_2022.387.issue-3;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2202809" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2202809" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2202809" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2202809" class="inputDoi"><input type="hidden" value="J. Cortes and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2022;387:217-226" class="inputCitation"><input type="hidden" value="07-20-2022" class="inputEPubDate"><input type="hidden" value="July 2022" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6de2914b00120-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Javier</span> <span property="familyName">Cortes</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-7623-1583" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-7623-1583</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Hope S.</span> <span property="familyName">Rugo</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">David W.</span> <span property="familyName">Cescon</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Seock-Ah</span> <span property="familyName">Im</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mastura M.</span> <span property="familyName">Yusof</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Carlos</span> <span property="familyName">Gallardo</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Oleg</span> <span property="familyName">Lipatov</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+12</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Carlos H.</span> <span property="familyName">Barrios</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jose</span> <span property="familyName">Perez-Garcia</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Hiroji</span> <span property="familyName">Iwata</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Norikazu</span> <span property="familyName">Masuda</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Marco</span> <span property="familyName">Torregroza Otero</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Erhan</span> <span property="familyName">Gokmen</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sherene</span> <span property="familyName">Loi</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Zifang</span> <span property="familyName">Guo</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Xuan</span> <span property="familyName">Zhou</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Vassiliki</span> <span property="familyName">Karantza</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Wilbur</span> <span property="familyName">Pan</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Peter</span> <span property="familyName">Schmid</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the KEYNOTE-355 Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-12</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">July 20, 2022</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2022<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">387</span></span>:<span property="pageStart">217</span>-<span property="pageEnd">226</span></div><div class="doi">DOI: 10.1056/NEJMoa2202809</div><div class="core-enumeration"><a href="/toc/nejm/387/3"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">387</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">3</span></span></a></div><div><a href="#tab-information">Copyright © 2022</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DJavier%2BCortes%252C%2BHope%2BS.%2BRugo%252C%2BDavid%2BW.%2BCescon%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D387%26issueNum%3D3%26contentID%3D10.1056%252FNEJMoa2202809%26title%3DPembrolizumab%2Bplus%2BChemotherapy%2Bin%2BAdvanced%2BTriple-Negative%2BBreast%2BCancer%26publicationDate%3D07%252F21%252F2022" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2202809" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DJavier%2BCortes%252C%2BHope%2BS.%2BRugo%252C%2BDavid%2BW.%2BCescon%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D387%26issueNum%3D3%26contentID%3D10.1056%252FNEJMoa2202809%26title%3DPembrolizumab%2Bplus%2BChemotherapy%2Bin%2BAdvanced%2BTriple-Negative%2BBreast%2BCancer%26publicationDate%3D07%252F21%252F2022" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/4714f06c-356d-4e93-ba1d-fbd27238d8aa/nejmoa2202809.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2202809.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2202809" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2202809" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2202809.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score (CPS; the number of PD-L1–staining tumor cells, lymphocytes, and macrophages, divided by the total number of viable tumor cells, multiplied by 100) of 10 or more. The results of the final analysis of overall survival have not been reported.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We randomly assigned patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer in a 2:1 ratio to receive pembrolizumab (200 mg) every 3 weeks plus the investigator’s choice of chemotherapy (nanoparticle albumin-bound paclitaxel, paclitaxel, or gemcitabine–carboplatin) or placebo plus chemotherapy. The primary end points were progression-free survival (reported previously) and overall survival among patients whose tumors expressed PD-L1 with a CPS of 10 or more (the CPS-10 subgroup), among patients whose tumors expressed PD-L1 with a CPS of 1 or more (the CPS-1 subgroup), and in the intention-to-treat population. Safety was also assessed.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><!-- There is no content. --><nav><a href="#f0" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202809_f0.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f0" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202809_f0.jpg"><img src="/cms/10.1056/NEJMoa2202809/asset/f60485f3-d7d0-42d9-bcc1-03dd84ff0a69/assets/images/large/nejmoa2202809_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 847 patients underwent randomization: 566 were assigned to the pembrolizumab–chemotherapy group, and 281 to the placebo–chemotherapy group. The median follow-up was 44.1 months. In the CPS-10 subgroup, the median overall survival was 23.0 months in the pembrolizumab–chemotherapy group and 16.1 months in the placebo–chemotherapy group (hazard ratio for death, 0.73; 95% confidence interval [CI], 0.55 to 0.95; two-sided P=0.0185 [criterion for significance met]); in the CPS-1 subgroup, the median overall survival was 17.6 and 16.0 months in the two groups, respectively (hazard ratio, 0.86; 95% CI, 0.72 to 1.04; two-sided P=0.1125 [not significant]); and in the intention-to-treat population, the median overall survival was 17.2 and 15.5 months, respectively (hazard ratio, 0.89; 95% CI, 0.76 to 1.05 [significance not tested]). Adverse events of grade 3, 4, or 5 that were related to the trial regimen occurred in 68.1% of the patients in the pembrolizumab–chemotherapy group and in 66.9% in the placebo–chemotherapy group, including death in 0.4% of the patients in the pembrolizumab–chemotherapy group and in no patients in the placebo–chemotherapy group.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Among patients with advanced triple-negative breast cancer whose tumors expressed PD-L1 with a CPS of 10 or more, the addition of pembrolizumab to chemotherapy resulted in significantly longer overall survival than chemotherapy alone. (Funded by Merck Sharp and Dohme; KEYNOTE-355 ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02819518" target="_blank">NCT02819518</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006591/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/52f555e1-1815-4ce7-a208-6a2355e87f35/media/NEJMdo006591_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006591/full/" class="ng-do-media_item-title-link">Pembrolizumab and Overall Survival in Triple-Negative Breast Cancer</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 17s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Triple-negative breast cancer is an aggressive breast cancer subtype that lacks expression of estrogen and progesterone receptors and amplification or overexpression of human epidermal growth factor receptor 2 (HER2).<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> The absence of these receptors renders endocrine and HER2-targeted therapies ineffective, leaving cytotoxic chemotherapy as the standard treatment option.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2" href-manipulated="true" aria-label="Reference 2">2</a></sup> However, chemotherapy results in suboptimal antitumor response rates and short overall survival and response durations.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3 r4 r5" id="body-ref-r5" href-manipulated="true">3-5</a></sup> New therapeutic strategies to improve outcomes are needed.</div><div role="paragraph">Pembrolizumab monotherapy has shown durable antitumor activity in advanced triple-negative breast cancer,<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r7 r8 r9" id="body-ref-r9-1" href-manipulated="true">6-9</a></sup> particularly as first-line therapy, with improved clinical responses observed among patients with higher programmed death ligand 1 (PD-L1) expression.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9-2" href-manipulated="true" aria-label="Reference 9">9</a></sup> The phase 3 KEYNOTE-355 trial examined whether the addition of pembrolizumab would enhance the antitumor activity of chemotherapy, including taxanes and a non-taxane platinum-based regimen, in patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer. Data from a prespecified interim analysis showed that pembrolizumab plus chemotherapy resulted in significantly longer progression-free survival than placebo plus chemotherapy among patients with a PD-L1 combined positive score (CPS) of 10 or more.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-1" href-manipulated="true" aria-label="Reference 10">10</a></sup> The CPS is the number of PD-L1–staining cells (tumor cells, lymphocytes, and macrophages) divided by the total number of viable tumor cells, multiplied by 100. Here, we present the results of the protocol-specified final analysis of the KEYNOTE-355 trial, which assessed overall survival among patients treated with pembrolizumab plus chemotherapy as compared with those who received placebo plus chemotherapy.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Patients</h3><div role="paragraph">As described previously,<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-2" href-manipulated="true" aria-label="Reference 10">10</a></sup> adult patients eligible for enrollment had centrally confirmed, locally recurrent inoperable or metastatic triple-negative breast cancer defined according to American Society of Clinical Oncology–College of American Pathologists guidelines<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11" href-manipulated="true" aria-label="Reference 11">11</a></sup>; measurable disease according to the Response Evaluation Criteria in Advanced Solid Tumors (RECIST), version 1.1<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12-1" href-manipulated="true" aria-label="Reference 12">12</a></sup>; an Eastern Cooperative Oncology Group performance-status score of 0 or 1 (on a 5-point scale, with higher numbers indicating greater disability)<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13" href-manipulated="true" aria-label="Reference 13">13</a></sup>; and adequate organ function. Patients who completed treatment for stage I, II, or III breast cancer were eligible if at least 6 months had elapsed between completion of treatment with curative intent (e.g., the date of primary breast tumor surgery or the date of the last administration of adjuvant chemotherapy, including capecitabine, whichever occurred last) and the first documented (by biopsy or imaging) local or distant disease recurrence. Adjuvant radiation therapy was acceptable for use during the 6-month interval requirement. Patients with new metastatic triple-negative breast cancer at initial diagnosis were also eligible for the trial. Patients who received taxane, gemcitabine, or platinum agents as neoadjuvant or adjuvant therapy could be treated with the same class of chemotherapy (a taxane or gemcitabine–carboplatin) if at least 12 months had elapsed between the completion of treatment with curative intent and the first documented local or distant disease recurrence.</div><div role="paragraph">Exclusion criteria were treatment with an investigational agent within 4 weeks before randomization or previous therapy that targeted programmed death 1, PD-L1, programmed death ligand 2, or an agent directed at another coinhibitory T-cell receptor; active autoimmune disease warranting systemic treatment within the previous 2 years; immunosuppressive therapy or diagnosis of immunodeficiency within the previous 1 week; active central nervous system metastases or carcinomatous meningitis (previously treated stable brain metastases were permitted); a history of noninfectious pneumonitis warranting glucocorticoids or current pneumonitis; or any active infection warranting systemic therapy.</div></section><section id="sec-1-2"><h3>Trial Design and Interventions</h3><div role="paragraph">In this phase 3, randomized, double-blind, international trial, eligible patients were randomly assigned in a 2:1 ratio to receive pembrolizumab (200 mg every 3 weeks) plus chemotherapy (investigator’s choice of nanoparticle albumin-bound [nab]–paclitaxel at a dose of 100 mg per square meter of body-surface area on days 1, 8, and 15 of every 28-day cycle; paclitaxel at a dose of 90 mg per square meter on days 1, 8, and 15 of every 28-day cycle; or gemcitabine at a dose of 1000 mg per square meter plus carboplatin [area under the concentration–time curve, 2] on days 1 and 8 of every 21-day cycle) or placebo plus chemotherapy for up to 35 intravenous administrations of pembrolizumab or placebo (chemotherapy was continued at the investigator’s discretion) or until confirmed disease progression or unacceptable toxic effects had occurred or withdrawal of consent or physician’s decision. Chemotherapy was administered on an open-label basis. A central interactive voice-response system with an integrated Web-response system was used for randomization. Stratification factors were the type of chemotherapy received during the trial (a taxane or gemcitabine–carboplatin), tumor PD-L1 expression (CPS ≥1 or CPS &lt;1), and previous treatment with the same class of neoadjuvant or adjuvant chemotherapy as that received during the trial (yes or no).</div></section><section id="sec-1-3"><h3>Assessments</h3><div role="paragraph">As described previously,<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-3" href-manipulated="true" aria-label="Reference 10">10</a></sup> response was assessed by imaging every 8 weeks until week 24, then every 9 weeks during the first year, and every 12 weeks thereafter on the basis of RECIST, version 1.1,<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12-2" href-manipulated="true" aria-label="Reference 12">12</a></sup> by blinded independent central review. After verified disease progression or initiation of new anticancer therapy, patients were monitored for survival status every 12 weeks. Baseline PD-L1 expression in archival or newly obtained formalin-fixed tumor samples was assessed at a central laboratory with the use of PD-L1 IHC 22C3 pharmDx (Agilent Technologies) and characterized according to the CPS.</div><div role="paragraph">Adverse events were monitored throughout the trial and for 30 days (90 days for serious adverse events) after discontinuation of the trial regimen and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14" href-manipulated="true" aria-label="Reference 14">14</a></sup> Immune-mediated adverse events were determined on the basis of a prespecified list of <i>Medical Dictionary for Regulatory Activities</i> (MedDRA) terms, which was updated with each new version of MedDRA.</div></section><section id="sec-1-4"><h3>End Points</h3><div role="paragraph">The primary end points were progression-free survival according to RECIST, version 1.1, as assessed by means of blinded independent central review, and overall survival among patients whose tumors expressed PD-L1 with a CPS of 10 or more (the CPS-10 subgroup), among patients whose tumors expressed PD-L1 with a CPS of 1 or more (the CPS-1 subgroup), and in the intention-to-treat population. Secondary efficacy end points included objective response, the duration of response, and disease control (complete response plus partial response plus stable disease for ≥24 weeks), all according to RECIST, version 1.1, and assessed by means of blinded independent central review. Safety was assessed among all patients who had received at least one dose of pembrolizumab, placebo, or chemotherapy.</div></section><section id="sec-1-5"><h3>Trial Oversight</h3><div role="paragraph">The trial was developed by academic advisors and employees of the sponsor. An external, independent data and safety monitoring committee oversaw the trial, periodically assessed safety, and assessed efficacy at prespecified interim analyses. The trial protocol and all amendments were approved by the appropriate ethics body at each participating institution. All patients provided written informed consent before enrollment.</div><div role="paragraph">All authors attest that the trial was conducted in accordance with the protocol, its amendments, and standards of Good Clinical Practice. The first draft of the manuscript was written by the first author with editorial assistance provided by a medical writer employed by the sponsor. All authors approved the submitted manuscript and vouch for the accuracy and completeness of the data and the fidelity of the trial to the <a href="#ap1">protocol</a> (available with the full text of this article at NEJM.org).</div></section><section id="sec-1-6"><h3>Statistical Analysis</h3><div role="paragraph">Details of the statistical analysis have been published previously.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-4" href-manipulated="true" aria-label="Reference 10">10</a></sup> In brief, efficacy was assessed in the intention-to-treat population, which included all patients who underwent randomization; safety was assessed among patients who underwent randomization and received at least one dose of pembrolizumab or placebo. The nonparametric Kaplan–Meier method was used to estimate progression-free survival, overall survival, and response curves in each group. The primary progression-free survival and overall survival hypotheses were tested with the use of the stratified log-rank test; hazard ratios and associated 95% confidence intervals were analyzed with the use of a stratified Cox proportional-hazards model with Efron’s method of tie handling to assess the magnitude of the between-group difference. The confidence intervals reported here are two-sided. The stratified Miettinen and Nurminen method<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15" href-manipulated="true" aria-label="Reference 15">15</a></sup> with strata weighting according to sample size was used to compare objective response and disease control between the two groups. The same stratification factors used for randomization were used in all stratified analyses.</div><div role="paragraph">The primary purpose of the final analysis was to perform formal statistical testing of overall survival. Formal statistical testing of other efficacy end points was completed at previous prespecified interim analyses, and updated descriptive analyses are provided. The familywise type I error rate across the primary and secondary hypotheses was strongly controlled at a two-sided alpha level of 0.05, which was split among the end points of progression-free survival (0.01), overall survival (0.036), and objective response (0.004) (see the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org). The group sequential method was used to allocate alpha between the interim and final analyses of overall survival, and alpha could be reallocated among hypotheses with the use of the graphical approach of Maurer and Bretz.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16" href-manipulated="true" aria-label="Reference 16">16</a></sup> For the analysis of overall survival, the initial alpha was assigned to the CPS-10 subgroup and the CPS-1 subgroup; the prespecified statistical criteria for this final analysis were an alpha level of 0.0227 for the CPS-10 subgroup and an alpha level of 0.013 (if the results for overall survival in the CPS-10 subgroup were not significant) or 0.0344 (if the results for overall survival in the CPS-10 subgroup were significant) for the CPS-1 subgroup. Overall survival in the intention-to-treat population could be tested only if the criterion for success with respect to overall survival in the CPS-1 subgroup was met. With a target of 240 deaths in the CPS-10 subgroup, the trial had an overall power of 79% to show superiority with respect to overall survival of pembrolizumab plus chemotherapy as compared with placebo plus chemotherapy at an initial two-sided overall alpha level of 0.02022 (before alpha reallocation), with an underlying hazard ratio of 0.65. The final analysis of overall survival was planned to be performed after approximately 664 deaths had occurred among all patients, approximately 482 deaths had occurred in the CPS-1 subgroup, and approximately 240 deaths had occurred in the CPS-10 subgroup. The protocol stated that the trial groups would be compared with the use of one-sided P values; however, in accordance with <i>Journal</i> policy, two-sided P values are reported here. Therefore, the two-sided overall alpha level and two-sided alpha boundaries are provided. The full statistical analysis plan is available with the protocol.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients and Interventions</h3><div role="paragraph">From January 2017 through June 2018, a total of 847 patients from 209 sites in 29 countries underwent randomization: 566 patients were assigned to the pembrolizumab–chemotherapy group and 281 to the placebo–chemotherapy group (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>). At the data-cutoff date (June 15, 2021), the median time since randomization was 44.1 months (range, 36.1 to 53.2). As reported previously,<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-5" href-manipulated="true" aria-label="Reference 10">10</a></sup> the baseline characteristics of the patients were well balanced between the two groups, and the baseline characteristics of the patients in the CPS-1 subgroup (636 patients [75.1%]) and the CPS-10 subgroup (323 patients [38.1%]) were similar to those of the intention-to-treat population (Table S1). Details regarding the representativeness of the trial patients are provided in Table S2. The median duration of exposure was 26.4 weeks in the pembrolizumab–chemotherapy group and 23.1 weeks in the placebo–chemotherapy group (Table S3).</div></section><section id="sec-2-2"><h3>Overall Survival</h3><div role="paragraph"><a id="exam-tint-one-b"></a><a id="exam-tint-one-d"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="one-b one-d">In the CPS-10 subgroup, 155 of 220 patients (70.5%) in the pembrolizumab–chemotherapy group and 84 of 103 patients (81.6%) in the placebo–chemotherapy group died. The median overall survival was 23.0 months (95% confidence interval [CI], 19.0 to 26.3) in the pembrolizumab–chemotherapy group and 16.1 months (95% CI, 12.6 to 18.8) in the placebo–chemotherapy group (hazard ratio for death, 0.73; 95% CI, 0.55 to 0.95; two-sided P=0.0185) (<a href="#f1">Figure 1A</a>). According to the prespecified criterion for statistical significance for the final analysis (an alpha level of 0.0227), the addition of pembrolizumab to chemotherapy resulted in significantly longer overall survival than chemotherapy alone.</span> The estimated overall survival at 18 months was 58.3% (95% CI, 51.4 to 64.5) in the pembrolizumab–chemotherapy group and 44.7% (95% CI, 34.9 to 53.9) in the placebo–chemotherapy group.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202809_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202809_f1.jpg"><img src="/cms/10.1056/NEJMoa2202809/asset/ea0e94f4-6d63-4521-a3ca-431565d42f5a/assets/images/large/nejmoa2202809_f1.jpg" height="3438" width="2362" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Overall Survival.</div><div class="notes"><div role="doc-footnote">Shown are Kaplan–Meier estimates of overall survival among patients whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score (CPS) of 10 or more (CPS-10 subgroup) (Panel A), among patients whose tumors expressed PD-L1 with a CPS of 1 or more (CPS-1 subgroup) (Panel B), and in the intention-to-treat population (Panel C). The CPS is the number of PD-L1–staining cells (tumor cells, lymphocytes, and macrophages) divided by the total number of viable tumor cells, multiplied by 100. Tick marks represent data censored at the last time the patient was known to be alive. The hazard ratios and confidence intervals were analyzed on the basis of a Cox regression model with treatment group as a covariate, with stratification according to the randomization stratification factors of the type of chemotherapy received in the trial (a taxane or gemcitabine–carboplatin), tumor PD-L1 expression (CPS ≥1 or CPS &lt;1), and previous treatment with the same class of neoadjuvant or adjuvant chemotherapy as that received in the trial (yes or no). The prespecified statistical criteria for significance for this final analysis were an alpha level of 0.0227 for the CPS-10 subgroup and an alpha level of 0.013 (if the results for overall survival in the CPS-10 subgroup were not significant) or 0.0344 (if the results for overall survival in the CPS-10 subgroup were significant) for the CPS-1 subgroup.</div></div></figcaption></figure></div><div role="paragraph"><a id="exam-tint-one-a"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="one-a">In the CPS-1 subgroup, 336 of 425 patients (79.1%) in the pembrolizumab–chemotherapy group and 177 of 211 patients (83.9%) in the placebo–chemotherapy group died. The median overall survival was 17.6 months (95% CI, 15.5 to 19.5) in the pembrolizumab–chemotherapy group and 16.0 months (95% CI, 12.8 to 17.4) in the placebo–chemotherapy group (hazard ratio for death, 0.86; 95% CI, 0.72 to 1.04; two-sided P=0.1125) (<a href="#f1">Figure 1B</a>). No significant between-group difference in overall survival was observed according to the prespecified criterion (an alpha level of 0.0344).</span> The estimated overall survival at 18 months was 48.4% (95% CI, 43.5 to 53.0) in the pembrolizumab–chemotherapy group and 41.4% (95% CI, 34.7 to 48.0) in the placebo–chemotherapy group.</div><div role="paragraph"><a id="exam-tint-one-c"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="one-c">In the intention-to-treat population, 460 of 566 patients (81.3%) in the pembrolizumab–chemotherapy group and 238 of 281 patients (84.7%) in the placebo–chemotherapy group died. The median overall survival was 17.2 months (95% CI, 15.3 to 19.0) in the pembrolizumab–chemotherapy group and 15.5 months (95% CI, 13.9 to 17.2) in the placebo–chemotherapy group (hazard ratio for death, 0.89; 95% CI, 0.76 to 1.05) (<a href="#f1">Figure 1C</a>). Significance was not tested because of the prespecified multiplicity strategy.</span> The estimated overall survival at 18 months was 47.8% (95% CI, 43.6 to 51.9) in the pembrolizumab–chemotherapy group and 41.8% (95% CI, 36.0 to 47.5) in the placebo–chemotherapy group. Log–log survival plots are provided in Figure S2 to support the proportional-hazards assumption for overall survival.</div><div role="paragraph">The treatment effect of pembrolizumab on overall survival increased with higher PD-L1 expression, with similar treatment effects observed among patients whose tumors expressed PD-L1 with a CPS of 10 or more and among those whose tumors expressed PD-L1 with a CPS of 20 or more (<a href="#f2">Figure 2</a>). The exploratory analysis of overall survival according to additional CPS cutoffs showed similar overall survival in the pembrolizumab–chemotherapy group and the placebo–chemotherapy group among patients whose tumors expressed PD-L1 with a CPS of less than 1 (hazard ratio, 0.97; 95% CI, 0.72 to 1.32) and among patients whose tumors expressed PD-L1 with a CPS of 1 to 9 (hazard ratio, 1.09; 95% CI, 0.85 to 1.40). The relative benefit of adding pembrolizumab to chemotherapy was similar among patients whose tumors expressed PD-L1 with a CPS of 10 to 19 (hazard ratio, 0.71; 95% CI, 0.46 to 1.09) and among those whose tumors expressed PD-L1 with a CPS of 20 or more (hazard ratio, 0.72; 95% CI, 0.51 to 1.01) (Fig. S3). The results of the analysis of overall survival in prespecified subgroups are shown in Figure S4.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202809_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202809_f2.jpg"><img src="/cms/10.1056/NEJMoa2202809/asset/ee89dd3e-1e07-46c9-84aa-691766916ed6/assets/images/large/nejmoa2202809_f2.jpg" height="1196" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Overall Survival in Subgroups According to PD-L1 CPS Status at Baseline.</div><div class="notes"><div role="doc-footnote">The analysis (hazard ratios and 95% confidence intervals) in the overall population used the stratified Cox regression model; the subgroup analyses used the unstratified Cox model.</div></div></figcaption></figure></div></section><section id="sec-2-3"><h3>Progression-free Survival</h3><div role="paragraph">The median progression-free survival in the CPS-10 subgroup was 9.7 months in the pembrolizumab–chemotherapy group and 5.6 months in the placebo–chemotherapy group (hazard ratio for progression or death, 0.66; 95% CI, 0.50 to 0.88). In the CPS-1 subgroup, the median progression-free survival was 7.6 months in the pembrolizumab–chemotherapy group and 5.6 months in the placebo–chemotherapy group (hazard ratio, 0.75; 95% CI, 0.62 to 0.91). In the intention-to-treat population, the median progression-free survival in the two groups was 7.5 and 5.6 months, respectively (hazard ratio, 0.82; 95% CI, 0.70 to 0.98) (Fig. S5).</div></section><section id="sec-2-4"><h3>Tumor Response</h3><div role="paragraph">In the CPS-10 subgroup, a confirmed objective response occurred in 116 of 220 patients (52.7%) in the pembrolizumab–chemotherapy group and in 42 of 103 (40.8%) in the placebo–chemotherapy group. In the CPS-1 subgroup, a confirmed objective response occurred in 191 of 425 patients (44.9%) in the pembrolizumab–chemotherapy group and in 82 of 211 (38.9%) in the placebo–chemotherapy group. In the intention-to-treat population, a confirmed objective response occurred in 231 of 566 patients (40.8%) in the pembrolizumab–chemotherapy group and in 104 of 281 (37.0%) in the placebo–chemotherapy group (Table S4). Among patients with a confirmed objective response, the duration of response was longer in the pembrolizumab–chemotherapy group than in the placebo–chemotherapy group. In the CPS-10 subgroup, the median duration of response was 12.8 months in the pembrolizumab–chemotherapy group and 7.3 months in the placebo–chemotherapy group (Table S4 and Fig. S6).</div></section><section id="sec-2-5"><h3>Safety</h3><div role="paragraph">Adverse events of any grade that were considered by the investigator to be related to the trial regimen occurred in 96.3% of 562 patients in the pembrolizumab–chemotherapy group and in 95.0% of 281 patients in the placebo–chemotherapy group. Anemia (in 49.1% of patients in the pembrolizumab–chemotherapy group and in 45.9% in the placebo–chemotherapy group), neutropenia (in 41.1% and 38.1%, respectively), and nausea (in 39.3% and 41.3%, respectively) were the most common adverse events (<a href="#t1">Table 1</a>). Adverse events related to the trial regimen that were of grade 3 or higher occurred in 68.1% and 66.9% of the patients in the two groups, respectively. <a id="exam-tint-two-a"></a><a id="exam-tint-two-b"></a><a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-b two-c two-d">As reported previously,<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-6" href-manipulated="true" aria-label="Reference 10">10</a></sup> adverse events related to the trial regimen led to death in 2 patients (0.4%) in the pembrolizumab–chemotherapy group (1 from acute kidney injury and 1 from pneumonia) and in no patients in the placebo–chemotherapy group.</span></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2202809_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2202809_t1.jpg"><img src="/cms/10.1056/NEJMoa2202809/asset/0454f96c-3c0f-4b91-943b-0673ffbb695d/assets/images/large/nejmoa2202809_t1.jpg" height="1760" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="2"><span>Pembrolizumab–Chemotherapy<br>(N=562)</span></th><th class="txxr-borders" colspan="2"><span>Placebo–Chemotherapy<br>(N=281)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 3, 4, or 5</th><th class="xxxx-borders">Any Grade</th><th class="xxxr-borders">Grade 3, 4, or 5</th></tr><tr class="head3" data-type="row head3" data-xml-valign="top"><td class="xxlx-borders hanging02">&nbsp;</td><th class="xxxr-borders" colspan="4"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">554 (98.6)</td><td class="xxxx-borders shading">438 (77.9)</td><td class="xxxx-borders shading">276 (98.2)</td><td class="xxxr-borders shading">207 (73.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Adverse events that were attributed to the trial regimen<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">541 (96.3)</td><td class="xxxx-borders">383 (68.1)</td><td class="xxxx-borders">267 (95.0)</td><td class="xxxr-borders">188 (66.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Anemia</td><td class="xxxx-borders shading">276 (49.1)</td><td class="xxxx-borders shading">93 (16.5)</td><td class="xxxx-borders shading">129 (45.9)</td><td class="xxxr-borders shading">41 (14.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Neutropenia</td><td class="xxxx-borders">231 (41.1)</td><td class="xxxx-borders">167 (29.7)</td><td class="xxxx-borders">107 (38.1)</td><td class="xxxr-borders">84 (29.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nausea</td><td class="xxxx-borders shading">221 (39.3)</td><td class="xxxx-borders shading">9 (1.6)</td><td class="xxxx-borders shading">116 (41.3)</td><td class="xxxr-borders shading">4 (1.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Alopecia</td><td class="xxxx-borders">186 (33.1)</td><td class="xxxx-borders">5 (0.9)</td><td class="xxxx-borders">94 (33.5)</td><td class="xxxr-borders">3 (1.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Fatigue</td><td class="xxxx-borders shading">161 (28.6)</td><td class="xxxx-borders shading">16 (2.8)</td><td class="xxxx-borders shading">84 (29.9)</td><td class="xxxr-borders shading">7 (2.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Neutrophil count decreased</td><td class="xxxx-borders">126 (22.4)</td><td class="xxxx-borders">98 (17.4)</td><td class="xxxx-borders">74 (26.3)</td><td class="xxxr-borders">57 (20.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Alanine aminotransferase increased</td><td class="xxxx-borders shading">115 (20.5)</td><td class="xxxx-borders shading">34 (6.0)</td><td class="xxxx-borders shading">46 (16.4)</td><td class="xxxr-borders shading">13 (4.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Immune-mediated adverse events<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">149 (26.5)</td><td class="xxxx-borders">30 (5.3)</td><td class="xxxx-borders">18 (6.4)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hypothyroidism</td><td class="xxxx-borders shading">89 (15.8)</td><td class="xxxx-borders shading">2 (0.4)</td><td class="xxxx-borders shading">9 (3.2)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hyperthyroidism</td><td class="xxxx-borders">24 (4.3)</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">3 (1.1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pneumonitis</td><td class="xxxx-borders shading">14 (2.5)</td><td class="xxxx-borders shading">6 (1.1)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Colitis</td><td class="xxxx-borders">10 (1.8)</td><td class="xxxx-borders">2 (0.4)</td><td class="xxxx-borders">4 (1.4)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Severe skin reactions</td><td class="xbxx-borders shading">10 (1.8)</td><td class="xbxx-borders shading">10 (1.8)<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xbxx-borders shading">1 (0.4)</td><td class="xbxr-borders shading">0</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Safety was assessed in all patients who had undergone randomization and received at least one dose of pembrolizumab, placebo, or chemotherapy. Listed are adverse events that occurred during the treatment period or within the 30 days thereafter (within 90 days for serious adverse events). Events are listed in descending order of frequency in the pembrolizumab–chemotherapy group. The severity of adverse events was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Patients may have had more than one adverse event.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Adverse events that were determined by the investigator to be related to the trial regimen and occurred in at least 20% of patients or events that were considered medically relevant are reported.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Immune-mediated adverse events were those included in a list of terms specified by the sponsor and were assessed regardless of attribution to the trial regimen. Events that occurred in at least 10 patients are reported.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Severe skin reactions included pruritus (in 1 patient), rash (in 4 patients), and maculopapular rash (in 6 patients).</div></div></div></figcaption></figure></div><div role="paragraph">Immune-mediated adverse events occurred in 26.5% of the patients in the pembrolizumab–chemotherapy group and in 6.4% in the placebo–chemotherapy group (<a href="#t1">Table 1</a>); these events were of grade 3 or 4 in 5.3% of the patients in the pembrolizumab–chemotherapy group and in no patients in the placebo–chemotherapy group. No patients died due to immune-mediated adverse events. The most common immune-mediated adverse events were hypothyroidism (in 15.8% in the pembrolizumab–chemotherapy group and in 3.2% in the placebo–chemotherapy group) and hyperthyroidism (in 4.3% and 1.1%, respectively).</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">The results of the protocol-specified second interim analysis of this trial showed that pembrolizumab plus chemotherapy resulted in significantly longer progression-free survival than chemotherapy alone among patients whose tumors expressed PD-L1 with a CPS of 10 or more.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-7" href-manipulated="true" aria-label="Reference 10">10</a></sup> The results of this protocol-specified final analysis showed that pembrolizumab plus chemotherapy also resulted in significantly longer overall survival than chemotherapy alone among patients whose tumors expressed PD-L1 with a CPS of 10 or more. The significance boundary for an overall survival benefit of pembrolizumab plus chemotherapy in the CPS-1 subgroup was not crossed, and formal testing in the intention-to-treat population was not performed. The results of an exploratory analysis of overall survival according to additional CPS cutoffs showed a consistent benefit with the addition of pembrolizumab among patients whose tumors expressed PD-L1 with a CPS of 10 to 19 and among those whose tumors expressed PD-L1 with a CPS of 20 or more; this finding provides further support that a CPS of 10 or more is an appropriate criterion to define the population of patients with advanced triple-negative breast cancer who would be expected to derive benefit from pembrolizumab plus chemotherapy.</div><div role="paragraph">As in the interim analysis,<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-8" href-manipulated="true" aria-label="Reference 10">10</a></sup> pembrolizumab plus chemotherapy provided a greater reduction in the risk of disease progression or death than chemotherapy alone; in the CPS-10 subgroup, the percentage of patients with progression-free survival at 12 months was approximately 16 percentage points higher in the pembrolizumab–chemotherapy group than in the placebo–chemotherapy group. The updated results for progression-free survival in the CPS-1 subgroup and the intention-to-treat population are also consistent with the previous results.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-9" href-manipulated="true" aria-label="Reference 10">10</a></sup> Similarly, the percentage of patients with an objective response is consistent with the previous interim data<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17" href-manipulated="true" aria-label="Reference 17">17</a></sup> and remains higher with pembrolizumab plus chemotherapy than with chemotherapy alone in both subgroups and in the intention-to-treat population, with the greatest benefit observed in the CPS-10 subgroup. Responses in the pembrolizumab–chemotherapy group were durable over longer follow-up, with the longest duration of response observed in the CPS-10 subgroup.</div><div role="paragraph">Our results build on findings from earlier trials involving patients with metastatic triple-negative breast cancer that showed greater single-agent activity with pembrolizumab and other immune checkpoint inhibitors with increasing PD-L1 expression.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8 r18 r19 r20" id="body-ref-r20" href-manipulated="true">7,8,18–20</a></sup> By contrast, the efficacy of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in early-stage triple-negative breast cancer was independent of PD-L1 expression.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21 r22" id="body-ref-r22" href-manipulated="true">21,22</a></sup> Together with similar observations in studies of atezolizumab for metastatic and early triple-negative breast cancer,<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23 r24" id="body-ref-r24" href-manipulated="true">23,24</a></sup> these observations suggest a differential role of baseline tumor PD-L1 expression in the efficacy of immune checkpoint inhibition for early-stage as compared with late-stage disease.</div><div role="paragraph">Our findings are generally consistent with those of the phase 3 IMpassion130 trial, which showed that the addition of atezolizumab to nab-paclitaxel as first-line treatment of metastatic triple-negative breast cancer resulted in significantly longer progression-free survival than placebo plus nab-paclitaxel (hazard ratio for progression or death, 0.80; 95% CI, 0.69 to 0.92; P=0.002 [in the intention-to-treat population]; hazard ratio, 0.62; 95% CI, 0.49 to 0.78; P&lt;0.001 [among patients with PD-L1–positive tumors, with the use of a different assay])<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23-2" href-manipulated="true" aria-label="Reference 23">23</a></sup> and numerically longer overall survival among patients with PD-L1–positive tumors than among patients with PD-L1–negative tumors (hazard ratio, 0.67; 95% CI, 0.53 to 0.86 [significance not formally tested]).<sup><a href="#core-r25" role="doc-biblioref" data-xml-rid="r25" id="body-ref-r25" href-manipulated="true" aria-label="Reference 25">25</a></sup> In the IMpassion131 trial, which evaluated a different chemotherapy backbone (paclitaxel rather than nab-paclitaxel),<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26" href-manipulated="true" aria-label="Reference 26">26</a></sup> combining atezolizumab with paclitaxel did not prolong progression-free survival or overall survival among patients with metastatic triple-negative breast cancer in either the PD-L1–positive or the intention-to-treat populations. In our trial, the benefit of pembrolizumab in the CPS-10 subgroup was observed with both paclitaxel and nab-paclitaxel, although these results should be interpreted with caution owing to the small number of patients who received paclitaxel.</div><div role="paragraph">After longer follow-up, the safety profile of pembrolizumab in combination with chemotherapy remained consistent with that in the previous analyses,<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-10" href-manipulated="true" aria-label="Reference 10">10</a></sup> with no evidence of cumulative toxic effects. Adverse events were consistent with the known safety profiles of pembrolizumab and the chemotherapy regimens, with no new safety signals. The most frequent adverse events related to the trial regimen in both groups (anemia, neutropenia, and nausea) reflect toxic effects typically associated with chemotherapy, and the addition of pembrolizumab did not increase the incidence of these adverse events or compromise exposure to chemotherapy. <a id="exam-tint-three-a"></a><a id="exam-tint-three-b"></a><a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-c three-d">As in the interim analysis,<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-11" href-manipulated="true" aria-label="Reference 10">10</a></sup> the higher incidence of immune-mediated adverse events in the pembrolizumab–chemotherapy group than in the placebo–chemotherapy group was primarily driven by hypothyroidism and hyperthyroidism. Overall, these events were generally low grade and were manageable with dose interruptions and appropriate use of supportive care.</span></div><div role="paragraph">In this trial, first-line treatment with pembrolizumab–chemotherapy resulted in significantly longer overall survival than chemotherapy alone among patients with advanced triple-negative breast cancer whose tumors expressed PD-L1 with a CPS of 10 or more.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Merck</span> Sharp and Dohme.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients and their families and caregivers for participating in this trial, all the investigators and site personnel, and the following current or former employees or contractors of Merck Sharp and Dohme: Gursel Aktan for trial oversight; Jing Zhao for supervision of statistical analyses; Aline Galvao, Krystal Bourdon, Laura Domrzalski, Karla Gonzalez, Deborah Card, Eleanor Readinger, Shana Hamm, Donna Letizia, Jennifer Kimmel, Roger Maxwell, and Craig Pritch for collection of data, supervision of research, provision of trial materials or patients, and administrative or logistic support; Melissa Lewis and Mercedes Bustamante for data management; Madhusudhan Reddy Papasani, Karuna Dhananjay Samudralwar, and Xuan Peng for statistical expertise; and Christine McCrary Sisk and Michele McColgan for medical writing and editorial assistance with an earlier version of the manuscript.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap0" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Research Summary</span> <span class="core-filename">(nejmoa2202809_research-summary.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2202809/suppl_file/nejmoa2202809_research-summary.pdf" download="nejmoa2202809_research-summary.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2202809_research-summary.pdf" data-doi="10.1056/NEJMoa2202809">Download</a></li><li>200.48 KB</li></ul></div></div><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2202809_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2202809/suppl_file/nejmoa2202809_protocol.pdf" download="nejmoa2202809_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2202809_protocol.pdf" data-doi="10.1056/NEJMoa2202809">Download</a></li><li>5.67 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2202809_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2202809/suppl_file/nejmoa2202809_appendix.pdf" download="nejmoa2202809_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2202809_appendix.pdf" data-doi="10.1056/NEJMoa2202809">Download</a></li><li>2.66 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2202809_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2202809/suppl_file/nejmoa2202809_disclosures.pdf" download="nejmoa2202809_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2202809_disclosures.pdf" data-doi="10.1056/NEJMoa2202809">Download</a></li><li>1.09 MB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2202809_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2202809/suppl_file/nejmoa2202809_data-sharing.pdf" download="nejmoa2202809_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2202809_data-sharing.pdf" data-doi="10.1056/NEJMoa2202809">Download</a></li><li>75.80 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Ahn SG, Kim SJ, Kim C, Jeong J. Molecular classification of triple-negative breast cancer. <em>J Breast Cancer</em> 2016;19:223-230.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4048/jbc.2016.19.3.223" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27721871/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000384386800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Molecular+classification+of+triple-negative+breast+cancer.&amp;publication_year=2016&amp;journal=J+Breast+Cancer&amp;pages=223-230&amp;doi=10.4048%2Fjbc.2016.19.3.223&amp;pmid=27721871" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Gucalp A, Traina TA. Triple-negative breast cancer: adjuvant therapeutic options. <em>Chemother Res Pract</em> 2011;2011:696208-696208.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22312556/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Triple-negative+breast+cancer%3A+adjuvant+therapeutic+options.&amp;publication_year=2011&amp;journal=Chemother+Res+Pract&amp;pages=696208-696208&amp;pmid=22312556" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Chaudhary LN, Wilkinson KH, Kong A. Triple-negative breast cancer: who should receive neoadjuvant chemotherapy? <em>Surg Oncol Clin N Am</em> 2018;27:141-153.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.soc.2017.08.004" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29132557/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000417341500011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Triple-negative+breast+cancer%3A+who+should+receive+neoadjuvant+chemotherapy%3F&amp;publication_year=2018&amp;journal=Surg+Oncol+Clin+N+Am&amp;pages=141-153&amp;doi=10.1016%2Fj.soc.2017.08.004&amp;pmid=29132557" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. <em>Clin Cancer Res</em> 2007;13:2329-2334.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-06-1109" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17438091/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000245883800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+triple+negative+paradox%3A+primary+tumor+chemosensitivity+of+breast+cancer+subtypes.&amp;publication_year=2007&amp;journal=Clin+Cancer+Res&amp;pages=2329-2334&amp;doi=10.1158%2F1078-0432.CCR-06-1109&amp;pmid=17438091" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. <em>J Clin Oncol</em> 2008;26:1275-1281.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2007.14.4147" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18250347/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000254178300016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Response+to+neoadjuvant+therapy+and+long-term+survival+in+patients+with+triple-negative+breast+cancer.&amp;publication_year=2008&amp;journal=J+Clin+Oncol&amp;pages=1275-1281&amp;doi=10.1200%2FJCO.2007.14.4147&amp;pmid=18250347" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. <em>J Clin Oncol</em> 2016;34:2460-2467.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2015.64.8931" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27138582/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000381497000005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+in+patients+with+advanced+triple-negative+breast+cancer%3A+phase+Ib+KEYNOTE-012+study.&amp;publication_year=2016&amp;journal=J+Clin+Oncol&amp;pages=2460-2467&amp;doi=10.1200%2FJCO.2015.64.8931&amp;pmid=27138582" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. <em>Ann Oncol</em> 2019;30:397-404.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdy517" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30475950/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000465084000012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+monotherapy+for+previously+treated+metastatic+triple-negative+breast+cancer%3A+cohort+A+of+the+phase+II+KEYNOTE-086+study.&amp;publication_year=2019&amp;journal=Ann+Oncol&amp;pages=397-404&amp;doi=10.1093%2Fannonc%2Fmdy517&amp;pmid=30475950" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in advanced triple-negative breast cancer, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with increasing PD-L1 expression. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. <em>Ann Oncol</em> 2019;30:405-411.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdy518" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30475947/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000465084000013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+monotherapy+for+previously+untreated%2C+PD-L1-positive%2C+metastatic+triple-negative+breast+cancer%3A+cohort+B+of+the+phase+II+KEYNOTE-086+study.&amp;publication_year=2019&amp;journal=Ann+Oncol&amp;pages=405-411&amp;doi=10.1093%2Fannonc%2Fmdy518&amp;pmid=30475947" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in advanced triple-negative breast cancer, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with increasing PD-L1 expression. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Winer EP, Lipatov O, Im S-A, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. <em>Lancet Oncol</em> 2021;22:499-511.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(20)30754-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33676601/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000637971400025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+versus+investigator-choice+chemotherapy+for+metastatic+triple-negative+breast+cancer+%28KEYNOTE-119%29%3A+a+randomised%2C+open-label%2C+phase+3+trial.&amp;publication_year=2021&amp;journal=Lancet+Oncol&amp;pages=499-511&amp;doi=10.1016%2FS1470-2045%2820%2930754-3&amp;pmid=33676601" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in advanced triple-negative breast cancer, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] death ligand 1 (PD-L1) expression. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. <em>Lancet</em> 2020;396:1817-1828.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)32531-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33278935/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000596010300023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+plus+chemotherapy+versus+placebo+plus+chemotherapy+for+previously+untreated+locally+recurrent+inoperable+or+metastatic+triple-negative+breast+cancer+%28KEYNOTE-355%29%3A+a+randomised%2C+placebo-controlled%2C+double-blind%2C+phase+3+clinical+trial.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=1817-1828&amp;doi=10.1016%2FS0140-6736%2820%2932531-9&amp;pmid=33278935" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] positive score (CPS) of 10 or more. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] As described previously, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] As described previously, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] analysis have been published previously. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] 36.1 to 53.2). As reported previously, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] As reported previously, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] expressed PD-L1 with a CPS of 10 or more. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>h [...] As in the interim analysis, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-9" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>i [...] also consistent with the previous results. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-10" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>j [...] with that in the previous analyses, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-11" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>k [...] As in the interim analysis, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. <em>J Clin Oncol</em> 2010;28:2784-2795.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2009.25.6529" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20404251/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000278108800020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=American+Society+of+Clinical+Oncology%2FCollege+Of+American+Pathologists+guideline+recommendations+for+immunohistochemical+testing+of+estrogen+and+progesterone+receptors+in+breast+cancer.&amp;publication_year=2010&amp;journal=J+Clin+Oncol&amp;pages=2784-2795&amp;doi=10.1200%2FJCO.2009.25.6529&amp;pmid=20404251" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). <em>Eur J Cancer</em> 2009;45:228-247.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ejca.2008.10.026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19097774/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000262948300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=New+response+evaluation+criteria+in+solid+tumours%3A+revised+RECIST+guideline+%28version+1.1%29.&amp;publication_year=2009&amp;journal=Eur+J+Cancer&amp;pages=228-247&amp;doi=10.1016%2Fj.ejca.2008.10.026&amp;pmid=19097774" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Advanced Solid Tumors (RECIST), version 1.1 </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] on the basis of RECIST, version 1.1, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. <em>Am J Clin Oncol</em> 1982;5:649-655.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/00000421-198212000-00014" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7165009/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1982PZ02100013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Toxicity+and+response+criteria+of+the+Eastern+Cooperative+Oncology+Group.&amp;publication_year=1982&amp;journal=Am+J+Clin+Oncol&amp;pages=649-655&amp;doi=10.1097%2F00000421-198212000-00014&amp;pmid=7165009" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">National Cancer Institute. Common terminology criteria for adverse events, version 4.0. 2010 (<a href="https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Common+terminology+criteria+for+adverse+events%2C+version+4.0&amp;publication_year=2010" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Miettinen O, Nurminen M. Comparative analysis of two rates. <em>Stat Med</em> 1985;4:213-226.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/sim.4780040211" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/4023479/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1985ALC2100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+analysis+of+two+rates.&amp;publication_year=1985&amp;journal=Stat+Med&amp;pages=213-226&amp;doi=10.1002%2Fsim.4780040211&amp;pmid=4023479" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Maurer W, Bretz F. Multiple testing in group sequential trials using graphical approaches. <em>Stat Biopharm Res</em> 2013;5:311-320.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/19466315.2013.807748" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000327394600004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Multiple+testing+in+group+sequential+trials+using+graphical+approaches&amp;publication_year=2013&amp;journal=Stat+Biopharm+Res&amp;pages=311-320&amp;doi=10.1080%2F19466315.2013.807748" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Rugo HS, Schmid P, Cescon DW, et al. Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab + chemotherapy versus placebo + chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC). In: Proceedings and Abstracts of the 2020 San Antonio Breast Cancer Virtual Symposium, December 8–11, 2020. San Antonio, TX: American Association for Cancer Research, 2020. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Additional+efficacy+endpoints+from+the+phase+3+KEYNOTE-355+study+of+pembrolizumab+%2B+chemotherapy+versus+placebo+%2B+chemotherapy+as+first-line+therapy+for+locally+recurrent+inoperable+or+metastatic+triple-negative+breast+cancer+%28mTNBC%29&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Cortes J, Lipatov O, Im S-A, et al. KEYNOTE-119: phase 3 study of pembrolizumab versus single-agent chemotherapy for metastatic triple-negative breast cancer (mTNBC). In: Proceedings and Abstracts of the 44th European Society for Medical Oncology Congress, September 27–October 1, 2019. Barcelona: European Society for Medical Oncology, 2019. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=KEYNOTE-119%3A+phase+3+study+of+pembrolizumab+versus+single-agent+chemotherapy+for+metastatic+triple-negative+breast+cancer+%28mTNBC%29&amp;publication_year=2019" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. <em>JAMA Oncol</em> 2019;5:74-82.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamaoncol.2018.4224" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30242306/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000455776100015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+clinical+outcomes+and+biomarker+analyses+of+atezolizumab+therapy+for+patients+with+metastatic+triple-negative+breast+cancer%3A+a+phase+1+study.&amp;publication_year=2019&amp;journal=JAMA+Oncol&amp;pages=74-82&amp;doi=10.1001%2Fjamaoncol.2018.4224&amp;pmid=30242306" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. <em>Breast Cancer Res Treat</em> 2018;167:671-686.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10549-017-4537-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29063313/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000424656700006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Avelumab%2C+an+anti-PD-L1+antibody%2C+in+patients+with+locally+advanced+or+metastatic+breast+cancer%3A+a+phase+1b+JAVELIN+Solid+Tumor+study.&amp;publication_year=2018&amp;journal=Breast+Cancer+Res+Treat&amp;pages=671-686&amp;doi=10.1007%2Fs10549-017-4537-5&amp;pmid=29063313" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. <em>N Engl J Med</em> 2020;382:810-821.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_22_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202809&amp;key=10.1056%2FNEJMoa1910549&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32101663/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000518581500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+for+early+triple-negative+breast+cancer.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=810-821&amp;doi=10.1056%2FNEJMoa1910549&amp;pmid=32101663" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. <em>N Engl J Med</em> 2022;386:556-567.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_23_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202809&amp;key=10.1056%2FNEJMoa2112651&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35139274/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000753100900011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Event-free+survival+with+pembrolizumab+in+early+triple-negative+breast+cancer.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=556-567&amp;doi=10.1056%2FNEJMoa2112651&amp;pmid=35139274" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. <em>N Engl J Med</em> 2018;379:2108-2121.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_24_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202809&amp;key=10.1056%2FNEJMoa1809615&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30345906/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000451402500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+and+nab-paclitaxel+in+advanced+triple-negative+breast+cancer.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=2108-2121&amp;doi=10.1056%2FNEJMoa1809615&amp;pmid=30345906" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and early triple-negative breast cancer, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] tumors, with the use of a different assay]) </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. <em>Lancet</em> 2020;396:1090-1100.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)31953-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32966830/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000579151000030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Neoadjuvant+atezolizumab+in+combination+with+sequential+nab-paclitaxel+and+anthracycline-based+chemotherapy+versus+placebo+and+chemotherapy+in+patients+with+early-stage+triple-negative+breast+cancer+%28IMpassion031%29%3A+a+randomised%2C+double-blind%2C+phase+3+trial.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=1090-1100&amp;doi=10.1016%2FS0140-6736%2820%2931953-X&amp;pmid=32966830" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. <em>Ann Oncol</em> 2021;32:983-993.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.annonc.2021.05.355" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34272041/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000685036900007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-line+atezolizumab+plus+nab-paclitaxel+for+unresectable%2C+locally+advanced%2C+or+metastatic+triple-negative+breast+cancer%3A+IMpassion130+final+overall+survival+analysis.&amp;publication_year=2021&amp;journal=Ann+Oncol&amp;pages=983-993&amp;doi=10.1016%2Fj.annonc.2021.05.355&amp;pmid=34272041" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. <em>Ann Oncol</em> 2021;32:994-1004.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.annonc.2021.05.801" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34219000/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000685036900008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Primary+results+from+IMpassion131%2C+a+double-blind%2C+placebo-controlled%2C+randomised+phase+III+trial+of+first-line+paclitaxel+with+or+without+atezolizumab+for+unresectable+locally+advanced%2Fmetastatic+triple-negative+breast+cancer.&amp;publication_year=2021&amp;journal=Ann+Oncol&amp;pages=994-1004&amp;doi=10.1016%2Fj.annonc.2021.05.801&amp;pmid=34219000" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/387/3"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">387</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">3</span></span> • <span property="datePublished">July 21, 2022</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">217</span>-<span property="pageEnd">226</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2022 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: July 20, 2022</div><div><b class="core-label">Published in issue</b>: July 21, 2022</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/breast-cancer" alt="View article keyword Breast Cancer" data-interactiontype="article_recirculation_click">Breast Cancer</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/treatments-in-oncology" alt="View article keyword Treatments in Oncology" data-interactiontype="article_recirculation_click">Treatments in Oncology</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Javier</span> <span property="familyName">Cortes</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-7623-1583" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-7623-1583</a></span>, <span property="author" typeof="Person"><span property="givenName">Hope S.</span> <span property="familyName">Rugo</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">David W.</span> <span property="familyName">Cescon</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Seock-Ah</span> <span property="familyName">Im</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mastura M.</span> <span property="familyName">Yusof</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Carlos</span> <span property="familyName">Gallardo</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Oleg</span> <span property="familyName">Lipatov</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Carlos H.</span> <span property="familyName">Barrios</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jose</span> <span property="familyName">Perez-Garcia</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Hiroji</span> <span property="familyName">Iwata</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Norikazu</span> <span property="familyName">Masuda</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Marco</span> <span property="familyName">Torregroza Otero</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Erhan</span> <span property="familyName">Gokmen</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sherene</span> <span property="familyName">Loi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Zifang</span> <span property="familyName">Guo</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Xuan</span> <span property="familyName">Zhou</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Vassiliki</span> <span property="familyName">Karantza</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Wilbur</span> <span property="familyName">Pan</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Peter</span> <span property="familyName">Schmid</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, for <span property="author" typeof="Person">the KEYNOTE-355 Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the International Breast Cancer Center, Pangaea Oncology, Quirónsalud Group, Barcelona (J.C., J.P.-G.), and the Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Madrid (J.C.) — both in Spain; the Department of Medicine, University of California San Francisco Comprehensive Cancer Center, San Francisco (H.S.R.); Princess Margaret Cancer Centre, Toronto (D.W.C.); Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul (S.-A.I.); Cancer Center at Pantai Hospital Kuala Lumpur, Kuala Lumpur, Malaysia (M.M.Y.); the Oncology Institute, Arturo Lopez Perez Foundation, Santiago, Chile (C.G.); the Department of Oncology, Republican Clinical Oncology Dispensary, Ufa, Russia (O.L.); the Oncology Research Unit, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil (C.H.B.); the Department of Breast Oncology, Aichi Cancer Center Hospital (H.I.), and the Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine (N.M.) — both in Nagoya, Japan; the Department of Hematology and Oncology, Oncomedica, Montería, Colombia (M.T.O.); Ege University Medical Faculty, Izmir, Turkey (E.G.); the Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville — both in Australia (S.L.); Merck, Rahway, NJ (Z.G., X.Z., V.K., W.P.); and the Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London (P.S.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Dr. Cortes can be contacted at <a href="mailto:jacortes@vhio.net">jacortes@vhio.net</a> or at the International Breast Cancer Center, Marquesa de Vilallonga 12, Barcelona 08017, Spain.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A complete list of investigators in the KEYNOTE-355 trial is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div><div role="doc-footnote"><div id="fn2" role="paragraph">Drs. Rugo and Schmid contributed equally to this article.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">594</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2202809" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="0870d5f8-bfa6-1aec-7a5e-c88bf8589060"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=132893668" style="display:inline-block;">
                <img alt="Article has an altmetric score of 865" src="https://badges.altmetric.com/?size=320&amp;score=865&amp;types=mabctwfd" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=132893668">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_0870d5f8-bfa6-1aec-7a5e-c88bf8589060" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=132893668&amp;tab=news">
          Picked up by <b>68</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=132893668&amp;tab=blogs">
          Blogged by <b>3</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=132893668&amp;tab=policy-documents">
          Referenced in <b>1</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=132893668&amp;tab=twitter">
          Posted by <b>710</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=132893668&amp;tab=patents">
          Referenced in <b>3</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=132893668&amp;tab=facebook">
          On <b>3</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=132893668&amp;tab=wikipedia">
          Referenced in <b>1</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=132893668&amp;tab=guidelines">
          Referenced in <b>3</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>441</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6de2914b00120-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2202809"> <input type="hidden" name="downloadFileName" value="csp_387_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2202809%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.387.issue-3%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="594" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">E. Arnaud, </li><li class="list-inline-item cited-by__entry__author">P. Vaflard, </li><li class="list-inline-item cited-by__entry__author">L. Escalup, </li><li class="list-inline-item cited-by__entry__author">T. Ramtohul, </li><li class="list-inline-item cited-by__entry__author">D. Meziani, </li><li class="list-inline-item cited-by__entry__author">L. Thibault, </li><li class="list-inline-item cited-by__entry__author">R.-P. Desmaris, </li><li class="list-inline-item cited-by__entry__author">J.-G. Feron, </li><li class="list-inline-item cited-by__entry__author">J.-Y. Pierga, </li><li class="list-inline-item cited-by__entry__author">L. Cabel, </li><li class="list-inline-item cited-by__entry__author">F. Lerebours, </li><li class="list-inline-item cited-by__entry__author">D. Loirat, </li><li class="list-inline-item cited-by__entry__author">P. Cottu, </li></ul><span class="cited-by__entry__title">Treatment toxicities and pathological response through the evolution of neoadjuvant regimens in early triple-negative breast cancer, </span><span class="cited-by__entry__series-title">ESMO Real World Data and Digital Oncology, </span><span class="cited-by__entry__volume"><strong>9</strong>, </span><span class="cited-by__entry__page-range">(100157), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.esmorw.2025.100157" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.esmorw.2025.100157</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.esmorw.2025.100157" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Giuseppina Roscigno, </li><li class="list-inline-item cited-by__entry__author">Sacha Jacobs, </li><li class="list-inline-item cited-by__entry__author">Belén Toledo, </li><li class="list-inline-item cited-by__entry__author">Roberto Borea, </li><li class="list-inline-item cited-by__entry__author">Gianluca Russo, </li><li class="list-inline-item cited-by__entry__author">Francesco Pepe, </li><li class="list-inline-item cited-by__entry__author">Maria Jose Serrano, </li><li class="list-inline-item cited-by__entry__author">Viola Calabrò, </li><li class="list-inline-item cited-by__entry__author">Giancarlo Troncone, </li><li class="list-inline-item cited-by__entry__author">Roberto Giovannoni, </li><li class="list-inline-item cited-by__entry__author">Elisa Giovannetti, </li><li class="list-inline-item cited-by__entry__author">Umberto Malapelle, </li></ul><span class="cited-by__entry__title">The potential application of stroma modulation in targeting tumor cells: Focus on pancreatic cancer and breast cancer models, </span><span class="cited-by__entry__series-title">Seminars in Cancer Biology, </span><span class="cited-by__entry__volume"><strong>113</strong>, </span><span class="cited-by__entry__page-range">(151-175), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.semcancer.2025.05.003" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.semcancer.2025.05.003</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.semcancer.2025.05.003" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Maria-Theodora Melissari, </li><li class="list-inline-item cited-by__entry__author">Alkistis Papatheodoridi, </li><li class="list-inline-item cited-by__entry__author">Athanasios Argyriadis, </li><li class="list-inline-item cited-by__entry__author">Maria Kaparelou, </li><li class="list-inline-item cited-by__entry__author">Meletios Athanasios Dimopoulos, </li><li class="list-inline-item cited-by__entry__author">Flora Zagouri, </li></ul><span class="cited-by__entry__title">Immunotherapy in primary hormone-receptor positive breast cancer: A systematic review, </span><span class="cited-by__entry__series-title">Critical Reviews in Oncology/Hematology, </span><span class="cited-by__entry__volume"><strong>212</strong>, </span><span class="cited-by__entry__page-range">(104768), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.critrevonc.2025.104768" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.critrevonc.2025.104768</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.critrevonc.2025.104768" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Maria Grazia Carnevale, </li><li class="list-inline-item cited-by__entry__author">Riccardo Ray Colciago, </li><li class="list-inline-item cited-by__entry__author">Maria Carmen De Santis, </li><li class="list-inline-item cited-by__entry__author">Laura Cortesi, </li><li class="list-inline-item cited-by__entry__author">Cinzia De Marco, </li><li class="list-inline-item cited-by__entry__author">Antonio Marra, </li><li class="list-inline-item cited-by__entry__author">Andrea Vingiani, </li><li class="list-inline-item cited-by__entry__author">Franco Nolè, </li><li class="list-inline-item cited-by__entry__author">Giuseppe Curigliano, </li><li class="list-inline-item cited-by__entry__author">Giancarlo Pruneri, </li><li class="list-inline-item cited-by__entry__author">Antonio Llombart-Cussac, </li><li class="list-inline-item cited-by__entry__author">Serena Di Cosimo, </li><li class="list-inline-item cited-by__entry__author">Javier Cortes, </li></ul><span class="cited-by__entry__title">Advancing breast cancer therapy in the era of molecular diagnostics, </span><span class="cited-by__entry__series-title">The Breast, </span><span class="cited-by__entry__volume"><strong>82</strong>, </span><span class="cited-by__entry__page-range">(104488), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.breast.2025.104488" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.breast.2025.104488</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.breast.2025.104488" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Giovanni Luca Beretta, </li><li class="list-inline-item cited-by__entry__author">Giuliana Cassinelli, </li><li class="list-inline-item cited-by__entry__author">Giacomina Rossi, </li><li class="list-inline-item cited-by__entry__author">Amalia Azzariti, </li><li class="list-inline-item cited-by__entry__author">Iléana Corbeau, </li><li class="list-inline-item cited-by__entry__author">Diego Tosi, </li><li class="list-inline-item cited-by__entry__author">Paola Perego, </li></ul><span class="cited-by__entry__title">Novel insights into taxane pharmacology: An update on drug resistance mechanisms, immunomodulation and drug delivery strategies, </span><span class="cited-by__entry__series-title">Drug Resistance Updates, </span><span class="cited-by__entry__volume"><strong>81</strong>, </span><span class="cited-by__entry__page-range">(101223), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.drup.2025.101223" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.drup.2025.101223</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.drup.2025.101223" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">María Gion, </li><li class="list-inline-item cited-by__entry__author">Isabel Blancas, </li><li class="list-inline-item cited-by__entry__author">Patricia Cortez-Castedo, </li><li class="list-inline-item cited-by__entry__author">Alfonso Cortés-Salgado, </li><li class="list-inline-item cited-by__entry__author">Frederik Marmé, </li><li class="list-inline-item cited-by__entry__author">Salvador Blanch, </li><li class="list-inline-item cited-by__entry__author">Serafín Morales, </li><li class="list-inline-item cited-by__entry__author">Nieves Díaz, </li><li class="list-inline-item cited-by__entry__author">Isabel Calvo-Plaza, </li><li class="list-inline-item cited-by__entry__author">Sabela Recalde, </li><li class="list-inline-item cited-by__entry__author">Alejandro Martínez-Bueno, </li><li class="list-inline-item cited-by__entry__author">Manuel Ruiz-Borrego, </li><li class="list-inline-item cited-by__entry__author">Elisenda Llabrés, </li><li class="list-inline-item cited-by__entry__author">María Teresa Taberner, </li><li class="list-inline-item cited-by__entry__author">Michelino de Laurentiis, </li><li class="list-inline-item cited-by__entry__author">Silvia García-Vicente, </li><li class="list-inline-item cited-by__entry__author">José Antonio Guerrero, </li><li class="list-inline-item cited-by__entry__author">Olga Boix, </li><li class="list-inline-item cited-by__entry__author">Jose Rodríguez-Morató, </li><li class="list-inline-item cited-by__entry__author">Miguel Sampayo-Cordero, </li><li class="list-inline-item cited-by__entry__author">Gabriele Antonarelli, </li><li class="list-inline-item cited-by__entry__author">José Manuel Pérez-García, </li><li class="list-inline-item cited-by__entry__author">Javier Cortés, </li><li class="list-inline-item cited-by__entry__author">Antonio Llombart-Cussac, </li></ul><span class="cited-by__entry__title">Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial, </span><span class="cited-by__entry__series-title">Nature Medicine, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41591-025-03734-3" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41591-025-03734-3</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41591-025-03734-3" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Elizabeth A. Mittendorf, </li><li class="list-inline-item cited-by__entry__author">Zoe June Assaf, </li><li class="list-inline-item cited-by__entry__author">Nadia Harbeck, </li><li class="list-inline-item cited-by__entry__author">Hong Zhang, </li><li class="list-inline-item cited-by__entry__author">Shigehira Saji, </li><li class="list-inline-item cited-by__entry__author">Kyung Hae Jung, </li><li class="list-inline-item cited-by__entry__author">Roberto Hegg, </li><li class="list-inline-item cited-by__entry__author">Andreas Koehler, </li><li class="list-inline-item cited-by__entry__author">Joohyuk Sohn, </li><li class="list-inline-item cited-by__entry__author">Hiroji Iwata, </li><li class="list-inline-item cited-by__entry__author">Melinda L. Telli, </li><li class="list-inline-item cited-by__entry__author">Cristiano Ferrario, </li><li class="list-inline-item cited-by__entry__author">Kevin Punie, </li><li class="list-inline-item cited-by__entry__author">Aditi Qamra, </li><li class="list-inline-item cited-by__entry__author">Max Dieterich, </li><li class="list-inline-item cited-by__entry__author">Yun Xu, </li><li class="list-inline-item cited-by__entry__author">Mario Liste-Hermoso, </li><li class="list-inline-item cited-by__entry__author">Esther Shearer-Kang, </li><li class="list-inline-item cited-by__entry__author">Luciana Molinero, </li><li class="list-inline-item cited-by__entry__author">Stephen Y. Chui, </li><li class="list-inline-item cited-by__entry__author">Carlos H. Barrios, </li></ul><span class="cited-by__entry__title">Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial, </span><span class="cited-by__entry__series-title">Nature Medicine, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41591-025-03725-4" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41591-025-03725-4</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41591-025-03725-4" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Fauzia Riaz, </li><li class="list-inline-item cited-by__entry__author">Joshua J. Gruber, </li><li class="list-inline-item cited-by__entry__author">Melinda L. Telli, </li></ul><span class="cited-by__entry__title">New Treatment Approaches for Triple-Negative Breast Cancer, </span><span class="cited-by__entry__series-title">American Society of Clinical Oncology Educational Book, </span><span class="cited-by__entry__volume"><strong>45</strong>, </span><span class="cited-by__entry__issue">3, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1200/EDBK-25-481154" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1200/EDBK-25-481154</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1200/EDBK-25-481154" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Shreastha Gautam, </li><li class="list-inline-item cited-by__entry__author">Rashmi Maurya, </li><li class="list-inline-item cited-by__entry__author">Akash Vikal, </li><li class="list-inline-item cited-by__entry__author">Preeti Patel, </li><li class="list-inline-item cited-by__entry__author">Shubham Thakur, </li><li class="list-inline-item cited-by__entry__author">Amandeep Singh, </li><li class="list-inline-item cited-by__entry__author">Ghanshyam Das Gupta, </li><li class="list-inline-item cited-by__entry__author">Balak Das Kurmi, </li></ul><span class="cited-by__entry__title">Understanding drug resistance in breast cancer: Mechanisms and emerging therapeutic strategies, </span><span class="cited-by__entry__series-title">Medicine in Drug Discovery, </span><span class="cited-by__entry__volume"><strong>26</strong>, </span><span class="cited-by__entry__page-range">(100210), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.medidd.2025.100210" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.medidd.2025.100210</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.medidd.2025.100210" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Dequan Liu, </li><li class="list-inline-item cited-by__entry__author">Lei Liu, </li><li class="list-inline-item cited-by__entry__author">Xinming Zhao, </li><li class="list-inline-item cited-by__entry__author">Xiaoman Zhang, </li><li class="list-inline-item cited-by__entry__author">Xiaochi Chen, </li><li class="list-inline-item cited-by__entry__author">Xiangyu Che, </li><li class="list-inline-item cited-by__entry__author">Guangzhen Wu, </li></ul><span class="cited-by__entry__title">A comprehensive review on targeting diverse immune cells for anticancer therapy: Beyond immune checkpoint inhibitors, </span><span class="cited-by__entry__series-title">Critical Reviews in Oncology/Hematology, </span><span class="cited-by__entry__volume"><strong>210</strong>, </span><span class="cited-by__entry__page-range">(104702), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.critrevonc.2025.104702" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.critrevonc.2025.104702</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.critrevonc.2025.104702" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2202809%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.387.issue-3%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2202809" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2202809" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2202809.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f0"><figure class="graphic"><a class="open-in-viewer" href="#f0" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202809_f0.jpg"><img src="/cms/10.1056/NEJMoa2202809/asset/f60485f3-d7d0-42d9-bcc1-03dd84ff0a69/assets/images/large/nejmoa2202809_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f0"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202809_f0.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202809_f1.jpg"><img src="/cms/10.1056/NEJMoa2202809/asset/ea0e94f4-6d63-4521-a3ca-431565d42f5a/assets/images/large/nejmoa2202809_f1.jpg" height="3438" width="2362" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Overall Survival.</div><div class="notes"><div role="doc-footnote">Shown are Kaplan–Meier estimates of overall survival among patients whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score (CPS) of 10 or more (CPS-10 subgroup) (Panel A), among patients whose tumors expressed PD-L1 with a CPS of 1 or more (CPS-1 subgroup) (Panel B), and in the intention-to-treat population (Panel C). The CPS is the number of PD-L1–staining cells (tumor cells, lymphocytes, and macrophages) divided by the total number of viable tumor cells, multiplied by 100. Tick marks represent data censored at the last time the patient was known to be alive. The hazard ratios and confidence intervals were analyzed on the basis of a Cox regression model with treatment group as a covariate, with stratification according to the randomization stratification factors of the type of chemotherapy received in the trial (a taxane or gemcitabine–carboplatin), tumor PD-L1 expression (CPS ≥1 or CPS &lt;1), and previous treatment with the same class of neoadjuvant or adjuvant chemotherapy as that received in the trial (yes or no). The prespecified statistical criteria for significance for this final analysis were an alpha level of 0.0227 for the CPS-10 subgroup and an alpha level of 0.013 (if the results for overall survival in the CPS-10 subgroup were not significant) or 0.0344 (if the results for overall survival in the CPS-10 subgroup were significant) for the CPS-1 subgroup.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202809_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202809_f2.jpg"><img src="/cms/10.1056/NEJMoa2202809/asset/ee89dd3e-1e07-46c9-84aa-691766916ed6/assets/images/large/nejmoa2202809_f2.jpg" height="1196" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Overall Survival in Subgroups According to PD-L1 CPS Status at Baseline.</div><div class="notes"><div role="doc-footnote">The analysis (hazard ratios and 95% confidence intervals) in the overall population used the stratified Cox regression model; the subgroup analyses used the unstratified Cox model.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202809_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2202809_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2202809/asset/0454f96c-3c0f-4b91-943b-0673ffbb695d/assets/images/large/nejmoa2202809_t1.jpg" height="1760" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders" colspan="2"><span>Pembrolizumab–Chemotherapy<br>(N=562)</span></th><th class="txxr-borders" colspan="2"><span>Placebo–Chemotherapy<br>(N=281)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Any Grade</th><th class="xxxx-borders">Grade 3, 4, or 5</th><th class="xxxx-borders">Any Grade</th><th class="xxxr-borders">Grade 3, 4, or 5</th></tr><tr class="head3" data-type="row head3" data-xml-valign="top"><td class="xxlx-borders hanging02">&nbsp;</td><th class="xxxr-borders" colspan="4"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">554 (98.6)</td><td class="xxxx-borders shading">438 (77.9)</td><td class="xxxx-borders shading">276 (98.2)</td><td class="xxxr-borders shading">207 (73.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Adverse events that were attributed to the trial regimen<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">541 (96.3)</td><td class="xxxx-borders">383 (68.1)</td><td class="xxxx-borders">267 (95.0)</td><td class="xxxr-borders">188 (66.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Anemia</td><td class="xxxx-borders shading">276 (49.1)</td><td class="xxxx-borders shading">93 (16.5)</td><td class="xxxx-borders shading">129 (45.9)</td><td class="xxxr-borders shading">41 (14.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Neutropenia</td><td class="xxxx-borders">231 (41.1)</td><td class="xxxx-borders">167 (29.7)</td><td class="xxxx-borders">107 (38.1)</td><td class="xxxr-borders">84 (29.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Nausea</td><td class="xxxx-borders shading">221 (39.3)</td><td class="xxxx-borders shading">9 (1.6)</td><td class="xxxx-borders shading">116 (41.3)</td><td class="xxxr-borders shading">4 (1.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Alopecia</td><td class="xxxx-borders">186 (33.1)</td><td class="xxxx-borders">5 (0.9)</td><td class="xxxx-borders">94 (33.5)</td><td class="xxxr-borders">3 (1.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Fatigue</td><td class="xxxx-borders shading">161 (28.6)</td><td class="xxxx-borders shading">16 (2.8)</td><td class="xxxx-borders shading">84 (29.9)</td><td class="xxxr-borders shading">7 (2.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Neutrophil count decreased</td><td class="xxxx-borders">126 (22.4)</td><td class="xxxx-borders">98 (17.4)</td><td class="xxxx-borders">74 (26.3)</td><td class="xxxr-borders">57 (20.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Alanine aminotransferase increased</td><td class="xxxx-borders shading">115 (20.5)</td><td class="xxxx-borders shading">34 (6.0)</td><td class="xxxx-borders shading">46 (16.4)</td><td class="xxxr-borders shading">13 (4.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Immune-mediated adverse events<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">149 (26.5)</td><td class="xxxx-borders">30 (5.3)</td><td class="xxxx-borders">18 (6.4)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Hypothyroidism</td><td class="xxxx-borders shading">89 (15.8)</td><td class="xxxx-borders shading">2 (0.4)</td><td class="xxxx-borders shading">9 (3.2)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Hyperthyroidism</td><td class="xxxx-borders">24 (4.3)</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">3 (1.1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Pneumonitis</td><td class="xxxx-borders shading">14 (2.5)</td><td class="xxxx-borders shading">6 (1.1)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Colitis</td><td class="xxxx-borders">10 (1.8)</td><td class="xxxx-borders">2 (0.4)</td><td class="xxxx-borders">4 (1.4)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Severe skin reactions</td><td class="xbxx-borders shading">10 (1.8)</td><td class="xbxx-borders shading">10 (1.8)<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xbxx-borders shading">1 (0.4)</td><td class="xbxr-borders shading">0</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Safety was assessed in all patients who had undergone randomization and received at least one dose of pembrolizumab, placebo, or chemotherapy. Listed are adverse events that occurred during the treatment period or within the 30 days thereafter (within 90 days for serious adverse events). Events are listed in descending order of frequency in the pembrolizumab–chemotherapy group. The severity of adverse events was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Patients may have had more than one adverse event.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Adverse events that were determined by the investigator to be related to the trial regimen and occurred in at least 20% of patients or events that were considered medically relevant are reported.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Immune-mediated adverse events were those included in a list of terms specified by the sponsor and were assessed regardless of attribution to the trial regimen. Events that occurred in at least 10 patients are reported.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Severe skin reactions included pruritus (in 1 patient), rash (in 4 patients), and maculopapular rash (in 6 patients).</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2202809_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2202809</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Ahn SG, Kim SJ, Kim C, Jeong J. Molecular classification of triple-negative breast cancer. <em>J Breast Cancer</em> 2016;19:223-230.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.4048/jbc.2016.19.3.223" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27721871/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000384386800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Molecular+classification+of+triple-negative+breast+cancer.&amp;publication_year=2016&amp;journal=J+Breast+Cancer&amp;pages=223-230&amp;doi=10.4048%2Fjbc.2016.19.3.223&amp;pmid=27721871" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Gucalp A, Traina TA. Triple-negative breast cancer: adjuvant therapeutic options. <em>Chemother Res Pract</em> 2011;2011:696208-696208.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/22312556/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Triple-negative+breast+cancer%3A+adjuvant+therapeutic+options.&amp;publication_year=2011&amp;journal=Chemother+Res+Pract&amp;pages=696208-696208&amp;pmid=22312556" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Chaudhary LN, Wilkinson KH, Kong A. Triple-negative breast cancer: who should receive neoadjuvant chemotherapy? <em>Surg Oncol Clin N Am</em> 2018;27:141-153.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.soc.2017.08.004" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29132557/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000417341500011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Triple-negative+breast+cancer%3A+who+should+receive+neoadjuvant+chemotherapy%3F&amp;publication_year=2018&amp;journal=Surg+Oncol+Clin+N+Am&amp;pages=141-153&amp;doi=10.1016%2Fj.soc.2017.08.004&amp;pmid=29132557" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. <em>Clin Cancer Res</em> 2007;13:2329-2334.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1078-0432.CCR-06-1109" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17438091/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000245883800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+triple+negative+paradox%3A+primary+tumor+chemosensitivity+of+breast+cancer+subtypes.&amp;publication_year=2007&amp;journal=Clin+Cancer+Res&amp;pages=2329-2334&amp;doi=10.1158%2F1078-0432.CCR-06-1109&amp;pmid=17438091" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. <em>J Clin Oncol</em> 2008;26:1275-1281.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2007.14.4147" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18250347/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000254178300016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Response+to+neoadjuvant+therapy+and+long-term+survival+in+patients+with+triple-negative+breast+cancer.&amp;publication_year=2008&amp;journal=J+Clin+Oncol&amp;pages=1275-1281&amp;doi=10.1200%2FJCO.2007.14.4147&amp;pmid=18250347" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. <em>J Clin Oncol</em> 2016;34:2460-2467.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2015.64.8931" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27138582/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000381497000005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+in+patients+with+advanced+triple-negative+breast+cancer%3A+phase+Ib+KEYNOTE-012+study.&amp;publication_year=2016&amp;journal=J+Clin+Oncol&amp;pages=2460-2467&amp;doi=10.1200%2FJCO.2015.64.8931&amp;pmid=27138582" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. <em>Ann Oncol</em> 2019;30:397-404.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdy517" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30475950/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000465084000012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+monotherapy+for+previously+treated+metastatic+triple-negative+breast+cancer%3A+cohort+A+of+the+phase+II+KEYNOTE-086+study.&amp;publication_year=2019&amp;journal=Ann+Oncol&amp;pages=397-404&amp;doi=10.1093%2Fannonc%2Fmdy517&amp;pmid=30475950" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in advanced triple-negative breast cancer, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with increasing PD-L1 expression. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. <em>Ann Oncol</em> 2019;30:405-411.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdy518" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30475947/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000465084000013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+monotherapy+for+previously+untreated%2C+PD-L1-positive%2C+metastatic+triple-negative+breast+cancer%3A+cohort+B+of+the+phase+II+KEYNOTE-086+study.&amp;publication_year=2019&amp;journal=Ann+Oncol&amp;pages=405-411&amp;doi=10.1093%2Fannonc%2Fmdy518&amp;pmid=30475947" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in advanced triple-negative breast cancer, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with increasing PD-L1 expression. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Winer EP, Lipatov O, Im S-A, et al. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. <em>Lancet Oncol</em> 2021;22:499-511.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r9-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(20)30754-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33676601/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000637971400025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+versus+investigator-choice+chemotherapy+for+metastatic+triple-negative+breast+cancer+%28KEYNOTE-119%29%3A+a+randomised%2C+open-label%2C+phase+3+trial.&amp;publication_year=2021&amp;journal=Lancet+Oncol&amp;pages=499-511&amp;doi=10.1016%2FS1470-2045%2820%2930754-3&amp;pmid=33676601" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r9-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r9-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] in advanced triple-negative breast cancer, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r9-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] death ligand 1 (PD-L1) expression. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. <em>Lancet</em> 2020;396:1817-1828.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)32531-9" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33278935/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000596010300023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+plus+chemotherapy+versus+placebo+plus+chemotherapy+for+previously+untreated+locally+recurrent+inoperable+or+metastatic+triple-negative+breast+cancer+%28KEYNOTE-355%29%3A+a+randomised%2C+placebo-controlled%2C+double-blind%2C+phase+3+clinical+trial.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=1817-1828&amp;doi=10.1016%2FS0140-6736%2820%2932531-9&amp;pmid=33278935" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] positive score (CPS) of 10 or more. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] As described previously, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] As described previously, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] analysis have been published previously. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] 36.1 to 53.2). As reported previously, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>f [...] As reported previously, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>g [...] expressed PD-L1 with a CPS of 10 or more. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-8" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>h [...] As in the interim analysis, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-9" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>i [...] also consistent with the previous results. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-10" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>j [...] with that in the previous analyses, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-11" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>k [...] As in the interim analysis, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. <em>J Clin Oncol</em> 2010;28:2784-2795.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2009.25.6529" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20404251/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000278108800020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=American+Society+of+Clinical+Oncology%2FCollege+Of+American+Pathologists+guideline+recommendations+for+immunohistochemical+testing+of+estrogen+and+progesterone+receptors+in+breast+cancer.&amp;publication_year=2010&amp;journal=J+Clin+Oncol&amp;pages=2784-2795&amp;doi=10.1200%2FJCO.2009.25.6529&amp;pmid=20404251" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). <em>Eur J Cancer</em> 2009;45:228-247.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ejca.2008.10.026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19097774/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000262948300002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=New+response+evaluation+criteria+in+solid+tumours%3A+revised+RECIST+guideline+%28version+1.1%29.&amp;publication_year=2009&amp;journal=Eur+J+Cancer&amp;pages=228-247&amp;doi=10.1016%2Fj.ejca.2008.10.026&amp;pmid=19097774" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r12-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] Advanced Solid Tumors (RECIST), version 1.1 </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r12-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] on the basis of RECIST, version 1.1, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. <em>Am J Clin Oncol</em> 1982;5:649-655.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/00000421-198212000-00014" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/7165009/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1982PZ02100013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Toxicity+and+response+criteria+of+the+Eastern+Cooperative+Oncology+Group.&amp;publication_year=1982&amp;journal=Am+J+Clin+Oncol&amp;pages=649-655&amp;doi=10.1097%2F00000421-198212000-00014&amp;pmid=7165009" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">National Cancer Institute. Common terminology criteria for adverse events, version 4.0. 2010 (<a href="https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Common+terminology+criteria+for+adverse+events%2C+version+4.0&amp;publication_year=2010" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Miettinen O, Nurminen M. Comparative analysis of two rates. <em>Stat Med</em> 1985;4:213-226.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/sim.4780040211" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/4023479/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1985ALC2100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+analysis+of+two+rates.&amp;publication_year=1985&amp;journal=Stat+Med&amp;pages=213-226&amp;doi=10.1002%2Fsim.4780040211&amp;pmid=4023479" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Maurer W, Bretz F. Multiple testing in group sequential trials using graphical approaches. <em>Stat Biopharm Res</em> 2013;5:311-320.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/19466315.2013.807748" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000327394600004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Multiple+testing+in+group+sequential+trials+using+graphical+approaches&amp;publication_year=2013&amp;journal=Stat+Biopharm+Res&amp;pages=311-320&amp;doi=10.1080%2F19466315.2013.807748" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Rugo HS, Schmid P, Cescon DW, et al. Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab + chemotherapy versus placebo + chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC). In: Proceedings and Abstracts of the 2020 San Antonio Breast Cancer Virtual Symposium, December 8–11, 2020. San Antonio, TX: American Association for Cancer Research, 2020. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Additional+efficacy+endpoints+from+the+phase+3+KEYNOTE-355+study+of+pembrolizumab+%2B+chemotherapy+versus+placebo+%2B+chemotherapy+as+first-line+therapy+for+locally+recurrent+inoperable+or+metastatic+triple-negative+breast+cancer+%28mTNBC%29&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Cortes J, Lipatov O, Im S-A, et al. KEYNOTE-119: phase 3 study of pembrolizumab versus single-agent chemotherapy for metastatic triple-negative breast cancer (mTNBC). In: Proceedings and Abstracts of the 44th European Society for Medical Oncology Congress, September 27–October 1, 2019. Barcelona: European Society for Medical Oncology, 2019. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=KEYNOTE-119%3A+phase+3+study+of+pembrolizumab+versus+single-agent+chemotherapy+for+metastatic+triple-negative+breast+cancer+%28mTNBC%29&amp;publication_year=2019" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. <em>JAMA Oncol</em> 2019;5:74-82.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamaoncol.2018.4224" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30242306/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000455776100015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+clinical+outcomes+and+biomarker+analyses+of+atezolizumab+therapy+for+patients+with+metastatic+triple-negative+breast+cancer%3A+a+phase+1+study.&amp;publication_year=2019&amp;journal=JAMA+Oncol&amp;pages=74-82&amp;doi=10.1001%2Fjamaoncol.2018.4224&amp;pmid=30242306" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. <em>Breast Cancer Res Treat</em> 2018;167:671-686.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s10549-017-4537-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29063313/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000424656700006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Avelumab%2C+an+anti-PD-L1+antibody%2C+in+patients+with+locally+advanced+or+metastatic+breast+cancer%3A+a+phase+1b+JAVELIN+Solid+Tumor+study.&amp;publication_year=2018&amp;journal=Breast+Cancer+Res+Treat&amp;pages=671-686&amp;doi=10.1007%2Fs10549-017-4537-5&amp;pmid=29063313" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. <em>N Engl J Med</em> 2020;382:810-821.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_22_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202809&amp;key=10.1056%2FNEJMoa1910549&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32101663/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000518581500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+for+early+triple-negative+breast+cancer.&amp;publication_year=2020&amp;journal=N+Engl+J+Med&amp;pages=810-821&amp;doi=10.1056%2FNEJMoa1910549&amp;pmid=32101663" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. <em>N Engl J Med</em> 2022;386:556-567.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_23_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202809&amp;key=10.1056%2FNEJMoa2112651&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35139274/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000753100900011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Event-free+survival+with+pembrolizumab+in+early+triple-negative+breast+cancer.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=556-567&amp;doi=10.1056%2FNEJMoa2112651&amp;pmid=35139274" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. <em>N Engl J Med</em> 2018;379:2108-2121.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r23-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_24_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2202809&amp;key=10.1056%2FNEJMoa1809615&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30345906/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000451402500006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+and+nab-paclitaxel+in+advanced+triple-negative+breast+cancer.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=2108-2121&amp;doi=10.1056%2FNEJMoa1809615&amp;pmid=30345906" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r23-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and early triple-negative breast cancer, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] tumors, with the use of a different assay]) </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Mittendorf EA, Zhang H, Barrios CH, et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. <em>Lancet</em> 2020;396:1090-1100.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r24"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(20)31953-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32966830/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000579151000030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Neoadjuvant+atezolizumab+in+combination+with+sequential+nab-paclitaxel+and+anthracycline-based+chemotherapy+versus+placebo+and+chemotherapy+in+patients+with+early-stage+triple-negative+breast+cancer+%28IMpassion031%29%3A+a+randomised%2C+double-blind%2C+phase+3+trial.&amp;publication_year=2020&amp;journal=Lancet&amp;pages=1090-1100&amp;doi=10.1016%2FS0140-6736%2820%2931953-X&amp;pmid=32966830" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Emens LA, Adams S, Barrios CH, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. <em>Ann Oncol</em> 2021;32:983-993.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.annonc.2021.05.355" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34272041/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000685036900007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=First-line+atezolizumab+plus+nab-paclitaxel+for+unresectable%2C+locally+advanced%2C+or+metastatic+triple-negative+breast+cancer%3A+IMpassion130+final+overall+survival+analysis.&amp;publication_year=2021&amp;journal=Ann+Oncol&amp;pages=983-993&amp;doi=10.1016%2Fj.annonc.2021.05.355&amp;pmid=34272041" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. <em>Ann Oncol</em> 2021;32:994-1004.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.annonc.2021.05.801" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34219000/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000685036900008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Primary+results+from+IMpassion131%2C+a+double-blind%2C+placebo-controlled%2C+randomised+phase+III+trial+of+first-line+paclitaxel+with+or+without+atezolizumab+for+unresectable+locally+advanced%2Fmetastatic+triple-negative+breast+cancer.&amp;publication_year=2021&amp;journal=Ann+Oncol&amp;pages=994-1004&amp;doi=10.1016%2Fj.annonc.2021.05.801&amp;pmid=34219000" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 20, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2207532" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Pembrolizumab in the Treatment of Breast Cancer</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">X. Pivot</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 12, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2210919" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Pembrolizumab in Triple-Negative Breast Cancer</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Norwalk, Connecticut</span></div><div><span>Endocrinology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885263/excellent-endocrinologist-opportunity-norwalk-area-connecticut-one-hour-from-new-york-city-/?query=fjwp&amp;rid=12925">Excellent Endocrinologist Opportunity, Norwalk area Connecticut - One Hour from New York City </a></div></div><div class="nejm-widget_item"><div><span> New York City, New York</span></div><div><span>Surgery, Transplant</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883926/surgical-director-for-pediatric-liver-transplantation/?query=fjwp&amp;rid=3059">Surgical Director for Pediatric Liver Transplantation</a></div></div><div class="nejm-widget_item"><div><span> Fond Du Lac, Wisconsin</span></div><div><span>Neurology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890092/neurology-opportunity-in-physician-owned-practice-with-shareholder-opportunity-fond-du-lac-wi/?query=fjwf&amp;rid=196467">Neurology Opportunity in Physician-Owned Practice with Shareholder Opportunity - Fond du Lac, WI</a></div></div><div class="nejm-widget_item"><div><span> Oklahoma City, Oklahoma</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/879956/hometown-family-medicine-physician-for-local-healthplex-moore-ok/?query=fjwf&amp;rid=196467">Hometown Family Medicine Physician for local Healthplex - Moore, OK</a></div></div><div class="nejm-widget_item"><div><span> Portsmouth, New Hampshire</span></div><div><span>Psychiatry</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891168/psychiatrist-outpatient-only/?query=fjwf&amp;rid=377088">Psychiatrist Outpatient Only</a></div></div><div class="nejm-widget_item"><div><span> Illinois</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883015/obgyn-j1-or-h1b-visa-established-group-high-volume-near-chicago/?query=fjwf&amp;rid=5263">OBGYN | J1 or H1B Visa | Established Group | High Volume | Near Chicago</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2202809&amp;pubId=41284494&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6de2914b00120-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6de2914b00120-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6de2914b00120-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$316189458$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$316189458$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$316189458$--></div></div><div class="mlt-body"><!--?lit$316189458$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$316189458$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$316189458$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$316189458$-->Nov 28, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2409932?query=recirc_Semantic" target="_self">Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer</a></div><div class="mlt-article-authors"><!--?lit$316189458$-->P. Schmid and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$316189458$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$316189458$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$316189458$-->Feb 10, 2022</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2112651?query=recirc_Semantic" target="_self">Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer</a></div><div class="mlt-article-authors"><!--?lit$316189458$-->P. Schmid and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$316189458$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$316189458$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$316189458$-->Mar 13, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2416491?query=recirc_Semantic" target="_self">Pembrolizumab in Early-Stage Triple-Negative Breast Cancer</a></div><div class="mlt-article-authors"><!--?lit$316189458$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$316189458$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$316189458$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$316189458$-->Mar 07, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2312117?query=recirc_Semantic" target="_self">Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer</a></div><div class="mlt-article-authors"><!--?lit$316189458$-->T. Powles and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$316189458$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$316189458$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$316189458$-->Jun 08, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2302312?query=recirc_Semantic" target="_self">Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer</a></div><div class="mlt-article-authors"><!--?lit$316189458$-->R.N. Eskander and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2202809?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2202809" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2202809.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2202809"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2206038" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Tirzepatide Once Weekly for the Treatment of Obesity</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2205011" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f0" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202809_f0.jpg"><img src="/cms/10.1056/NEJMoa2202809/asset/f60485f3-d7d0-42d9-bcc1-03dd84ff0a69/assets/images/large/nejmoa2202809_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title"></div><div class="fv__item__description"><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202809_f1.jpg"><img src="/cms/10.1056/NEJMoa2202809/asset/ea0e94f4-6d63-4521-a3ca-431565d42f5a/assets/images/large/nejmoa2202809_f1.jpg" height="3438" width="2362" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Overall Survival.</div><div class="notes"><div role="doc-footnote">Shown are Kaplan–Meier estimates of overall survival among patients whose tumors expressed programmed death ligand 1 (PD-L1) with a combined positive score (CPS) of 10 or more (CPS-10 subgroup) (Panel A), among patients whose tumors expressed PD-L1 with a CPS of 1 or more (CPS-1 subgroup) (Panel B), and in the intention-to-treat population (Panel C). The CPS is the number of PD-L1–staining cells (tumor cells, lymphocytes, and macrophages) divided by the total number of viable tumor cells, multiplied by 100. Tick marks represent data censored at the last time the patient was known to be alive. The hazard ratios and confidence intervals were analyzed on the basis of a Cox regression model with treatment group as a covariate, with stratification according to the randomization stratification factors of the type of chemotherapy received in the trial (a taxane or gemcitabine–carboplatin), tumor PD-L1 expression (CPS ≥1 or CPS &lt;1), and previous treatment with the same class of neoadjuvant or adjuvant chemotherapy as that received in the trial (yes or no). The prespecified statistical criteria for significance for this final analysis were an alpha level of 0.0227 for the CPS-10 subgroup and an alpha level of 0.013 (if the results for overall survival in the CPS-10 subgroup were not significant) or 0.0344 (if the results for overall survival in the CPS-10 subgroup were significant) for the CPS-1 subgroup.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2202809_f2.jpg"><img src="/cms/10.1056/NEJMoa2202809/asset/ee89dd3e-1e07-46c9-84aa-691766916ed6/assets/images/large/nejmoa2202809_f2.jpg" height="1196" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Overall Survival in Subgroups According to PD-L1 CPS Status at Baseline.</div><div class="notes"><div role="doc-footnote">The analysis (hazard ratios and 95% confidence intervals) in the overall population used the stratified Cox regression model; the subgroup analyses used the unstratified Cox model.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/387/3" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 387 No. 3</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 21, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2119913" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">P. Chowdary and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 21, 2022</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2205011" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">C.J. Cohen-Stavi and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jul 21, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2206038" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Tirzepatide Once Weekly for the Treatment of Obesity</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">A.M. Jastreboff and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2202809%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2202809&amp;pubId=41284494&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2202809%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2202809&amp;pubId=41284494&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id07247973113485305" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6de2914b00120-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6de2914b00120-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6de2914b00120-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6de2914b00120-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6de2914b00120-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6de2914b00120-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6de2914b00120-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6de2914b00120-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6de2914b00120-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6de2914b00120-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6de290c640120',t:'MTc0OTUzNzUyNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6de290c640120&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><zvl-iisoyazvytbp></zvl-iisoyazvytbp><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2202809?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=3-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" data-transactionid="qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" id="captureIFrame_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" target="captureIFrame_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" name="capture_screen"><input id="capture_signIn_js_version_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" name="js_version"><input id="capture_signIn_transactionId_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" data-capturefield="undefined" value="qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" type="hidden" class="capture_transactionId_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" name="capture_transactionId"><input id="capture_signIn_form_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" name="form"><input id="capture_signIn_flow_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" name="flow"><input id="capture_signIn_client_id_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" name="client_id"><input id="capture_signIn_redirect_uri_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" name="redirect_uri"><input id="capture_signIn_response_type_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" name="response_type"><input id="capture_signIn_flow_version_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" name="flow_version"><input id="capture_signIn_settings_version_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" name="settings_version"><input id="capture_signIn_locale_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" name="locale"><input id="capture_signIn_recaptcha_version_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_qo78cu45c4gdcyspwnr21rz6ltl7r4d0pfugm2kb" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>